Naltrexone has variable and schedule-dependent effects on oral squamous cell carcinoma cells
Kazmi, S.; Sanford, E.; Rammaha, Z. A.; Gao, F.; Sangalli, L.; Roberts, C. M.
Show abstract
Oral squamous cell carcinoma is marked by profound differences in survival between localized and disseminated disease. While at its site of origin, oral cancer is frequently treated with surgery and/or radiation, leading to approximately 70% five-year survival. In metastatic cases, chemotherapy is preferred, but drug resistance and therapy failure is common in this setting, leading to five-year survival below 40%. New therapeutic approaches are therefore needed to supplement existing chemotherapies and improve outcomes. Naltrexone, an opioid antagonist most well-known for treatment of substance abuse, has been evaluated at low doses in other contexts, including inflammation, autoimmunity, and other forms of cancer. In this study, we sought to determine if intermittent dosing of naltrexone would impact oral cancer cell survival, either as a single agent or in combination with traditional chemotherapy. We found that its effects alone were negligible, but that combination with cytotoxic drugs may have promise as a novel treatment strategy. Further study and optimization will be needed to determine if these findings will be of clinical benefit.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: Implications for the involvement of pirin 90%
- Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma 89%
- Bioluminescent zebrafish transplantation model for drug discovery 89%
Similar papers in this journal
- Suppression of Ovarian Cancer Cell Proliferation is Associated with Upregulation of Cell-Matrix Adhesion Programs and Integrin-β4-Induced Cell Protection from Cisplatin. 91%
- Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting 91%
- Tegaserod maleate suppresses the growth of gastric cancer in vivo and in vitro by targeting MEK1/2 91%
Similar papers in this journal
- Comprehensive Live-cell Imaging Analysis of Cryptotanshinone and Synergistic Drug-Screening Effects in Various Human and Canine Cancer Cell Lines 93%
- A cautionary note on the use of N-acetylcysteine as a reactive oxygen species antagonist to assess copper mediated cell death. 93%
- Reshaping the Landscape of Locoregional Treatments for Breast Cancer Liver Metastases: A novel, intratumoral, p21-targeted percutaneous therapy increases survival in BALB/c mice inoculated with 4T1 triple negative breast cancer cells in the liver. 92%
Similar papers in this journal
- A pro-oxidant combination of resveratrol and copper down-regulates hallmarks of cancer and immune checkpoints in patients with advanced oral cancer: Results of an exploratory study (RESCU 004) 94%
- Augmentation of extracellular ATP synergizes with chemotherapy in triple negative breast cancer 94%
- mTOR inhibitors as radiosensitizers in neuroendocrine neoplasms 92%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.